| Darius Alexander Filsoof, MD | |
|
1223 16th St Ste 3400, Santa Monica, CA 90404-1279 | |
| (310) 449-0939 | |
| (424) 259-7790 |
| Full Name | Darius Alexander Filsoof |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 1223 16th St Ste 3400, Santa Monica, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801250584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A150985 (California) | Primary |
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
A new report issued by Blue Cross and Blue Shield of Minnesota (Blue Cross) shows that each year, smoking is responsible for 5,135 deaths in Minnesota and $2.87 billion in excess medical costs to treat diseases caused by smoking. The report, titled "Health Care Costs and Smoking in Minnesota," was completed by Jeffrey Fellows, Ph.D., and a nationally known health economist from the Center for Health Research at Kaiser Permanente Northwest.
As the clinical use of genomic testing expands, the practical and ethical considerations of using the technology to screen newborns for genetic conditions will be the focus of a new study undertaken at the University of North Carolina.
Today the Society for Cardiovascular Angiography and Interventions announced the publication of recommendations for assessing and improving program quality at percutaneous coronary intervention programs at cardiac facilities.
GVK Biosciences, Asia's leading drug discovery research & development organization announced today that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Darius Alexander Filsoof, MD 5767 W Century Blvd Ste 400, Los Angeles, CA 90045-5631 Ph: (310) 301-8707 | Darius Alexander Filsoof, MD 1223 16th St Ste 3400, Santa Monica, CA 90404-1279 Ph: (310) 449-0939 |
News Archive
A new report issued by Blue Cross and Blue Shield of Minnesota (Blue Cross) shows that each year, smoking is responsible for 5,135 deaths in Minnesota and $2.87 billion in excess medical costs to treat diseases caused by smoking. The report, titled "Health Care Costs and Smoking in Minnesota," was completed by Jeffrey Fellows, Ph.D., and a nationally known health economist from the Center for Health Research at Kaiser Permanente Northwest.
As the clinical use of genomic testing expands, the practical and ethical considerations of using the technology to screen newborns for genetic conditions will be the focus of a new study undertaken at the University of North Carolina.
Today the Society for Cardiovascular Angiography and Interventions announced the publication of recommendations for assessing and improving program quality at percutaneous coronary intervention programs at cardiac facilities.
GVK Biosciences, Asia's leading drug discovery research & development organization announced today that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
› Verified 4 days ago
Irawan Susanto, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St, Suite 3400, Santa Monica, CA 90404 Phone: 310-449-0939 Fax: 424-259-7790 | |
Louis Ravitz, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2336 Santa Monica Blvd, Suite 207, Santa Monica, CA 90404 Phone: 310-828-9311 Fax: 310-453-8533 | |
Janet Winikoff, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2001 Santa Monica Blvd Ste 860, Santa Monica, CA 90404 Phone: 310-828-3209 Fax: 310-828-5165 | |
Dr. Sean Dooley, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2121 Santa Monica Blvd, Santa Monica, CA 90404 Phone: 323-829-8745 | |
Lorraine Anderson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1245 16th St Ste 303, Santa Monica, CA 90404 Phone: 310-481-4646 Fax: 310-899-7599 | |
Dr. Colleen Lucy Channick, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 | |
Carol Yukiko Nishikubo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404 Phone: 310-453-5654 Fax: 310-453-6885 |